The increasing number of obese patients worldwide has resulted in an increase in surgical procedures in this population. 1 2 The pharmacokinetic (PK) properties of some drugs are known to alter in obesity. 3 4 Although body fat has minimal metabolic activity, fat mass contributes to overall body size and may have an indirect influence on both metabolic and renal clearance. However, the volume of distribution of a drug depends on its physicochemical properties, 5 and there are drugs whose apparent volume of distribution is independent of fat mass (e.g. digoxin) 6 or is extensively determined by it (e.g. diazepam). 7 8 Consequently, changes in body composition in obesity require a strategy for dose adjustment. 2 Propofol is commonly used for induction and maintenance of general anaesthesia in obese patients. 9 -11 A controversial issue for propofol dose adjustment in this population has been the selection of an adequate size descriptor to scale PK parameters. 12 13 In normal-weight subjects, total body weight (TBW) is often used as a size descriptor. 12 However, in obese patients, adipose tissue and LBM do not increase proportionally and the percentage of lean body tissue per kg of TBW decreases. 4 13 14 A number of descriptors of body size have been proposed to scale doses in the obese, 13 15 but it is unclear which best describes the relationship between propofol dose and its plasma concentrations in this population.
Studies of propofol PK in obese are scarce and come from a small number of patients. A study in eight morbidly obese patients showed that compared with lean adults, the initial volume of distribution was not modified in obese patients. 16 It also found that total body clearance and volume of distribution at steady state correlated to TBW. The authors concluded that dose schemes based on TBW are the same as those in non-obese patients with no risk of accumulation. However, this scaling may result in the administration of largish doses of propofol with the inherent risk of haemodynamic adverse consequences.
We have investigated propofol PK in obese and non-obese subjects using a population-based approach to predict sources of the variability in propofol PK parameters. The objective of this study is to develop an integrated PK model to characterize the influence of obesity on propofol PK parameters.
Methods
Data from three sources were used for analysis.
Study 1
Schnider and colleagues 17 
PK analysis
The analysis composed of two parts:
(i) Time-concentration data profiles from Study 3 (n¼19, number of samples¼163). (ii) Time-concentration data profiles from this current study of adults administered propofol (Study 3) were pooled with data from Studies 1-2, 16 17 available at http://www.opentci.org. There were 51 subjects who contributed 1482 observations.
Population parameter estimations
A three-compartment mamillary model was used for the propofol PK. Population parameter estimates were obtained using a non-linear mixed effects model (NONMEM VI, Globomax LLC, Hanover, MD, USA). 21 The population mean parameters, between-subject variance, and residual variance were estimated using the first-order conditional estimation method using ADVAN 11 TRANS 4 of NONMEM VI. Convergence criterion was three significant digits.
The population parameter variability is modelled in terms of random effect (h) variables. Each of these variables is assumed to have a mean 0 and a variance denoted by v 2 , which is estimated. The between-subject variability in model parameters was modelled by exponentiating random effects (equivalent to assuming a log-normal distribution).
where P i is the parameter value (e.g. CL and V) of the ith patient, P TV the typical value of the parameter in the population, and h the random variable. We report the estimate of v for each variability component expressed as a percentage because these quantities are approximate coefficients of variation for a log-normal distribution.
The covariance between two elements of h (e.g. CL and V) is a measure of statistical association between these two variables. Their covariance is related to their correlation, that is,
The covariance of clearance and distribution volume variability was estimated. Separate proportional terms were applied to each of the three studies to characterize the residual unknown variability (RUV).
Covariate analysis

Size
The parameter values were standardized for a body size of 70 kg using an allometric model. 22 23
where P i is the parameter of the ith individual, X i a measure of body size of the ith individual, and P std the parameter in an individual with a standard size W std . The PWR exponent is 1 for both clearance and distribution volumes when the linear model is used and 0.75 for clearance and 1 for distribution volumes with the allometric model. 24 -26 Thus, total drug clearance may be expected to scale with a power of 3/4 with the allometric model:
where CL std is the population estimates for CL. We investigated four measures of body size (i) total body weight (TBW) (kg) (ii) lean body weight (LBW) 27 LBW (male) = 1.10 × TBW − 0.0128 × BMI × TBW 
Quality of fit
The quality of fit of the PK model to the data was judged by NONMEM's objective function. Models were nested and an improvement in the objective function was referred to the x 2 distribution to assess significance, for example, an objective function change (OBJ) of 3.84 is significant at a¼0.05. The phenomenon of shrinkage may occur where uninformative data lead to individual parameter predictions that shrink towards the population mean. Use of these shrinkage Propofol pharmacokinetics in the obese estimates can both miss important covariates and suggest spurious relationships. 30 Bootstrap methods, incorporated within the Wings for NONMEM program, provided a means to evaluate parameter uncertainty. 31 A total of 1000 replications were used to estimate parameter confidence intervals. A visual predictive check (VPC), 32 a modelling tool that estimates the concentration prediction intervals and graphically superimposes these intervals on observed concentrations after a standardized dose, was used to evaluate how well the model predicted the distribution of observed propofol concentrations. Simulation was performed using 1000 subjects with characteristics taken from studied patients. This is an advanced internal method of evaluation 33 34 and is considered better than the commonly used plots of observed vs predicted values. 33 34 For data such as these where covariates such as dose, weight, height, and sex are different for each patient, we used a prediction corrected VPC (PC-VPC). 35 Observations and simulations are multiplied by the population baseline value divided by the individual-estimated baseline.
Simulated TCI scenario
Computer simulations based on the PK described by Marsh and colleagues, 36 Schnider and colleagues, 17 and the current pooled PK model are performed to visually compare the PK profile of propofol predicted by these three models in obese patients. The simulation used a 30-yr-old female with TBW 140 kg, height 160 cm, and BMI 54.7 kg m 22 .
First, the predicted infusion rates needed to reach and maintain a target plasma propofol concentration of 3.0 mg ml 21 over 180 min are calculated. Then, the recovery profiles predicted by these three models are compared by means of the estimated context-sensitive half-time and 80% decrement time. 37 38 Computer simulations were performed with the Anestfusor TM TCI program.
Results
The obesity study involved 19 adults who contributed 163 observations ( assay samples in these subjects were available for study. The best linear model was that using TBW (OBJ 23214.91).
The allometric 3/4 power exponent on TBW for clearance was superior to the linear TBW model (DOBJ 7.389). This allometric model using TBW was not improved by the use of other size descriptor (FFM, LBW, NFM). The addition of age functions to both V2 and Q2 decreased the OBJ (DOBJ 43.484) and showed both parameters decreased with age. V2 decreased by 1.6% and Q2 by 1.5% per year (Supplementary Table S1 ). This final allometric model was better than that using a linear TBW model (DOBJ 15.371).
PK parameters were estimated with reasonable precision, and with an alternative parameterization based on the typical values showed for volumes and clearances (Supplementary Table S2A and B). The correlation of betweensubject variability for structural parameters showed the residual errors for the three studies were similar-the proportional errors were 31% in the index study and 30%, 22% for the other two studies (Supplementary Table S3 ). The final model used common proportional error to explain residual unexplained variability (RUV) without any change in structural parameter estimates (RUV 24.4%, CV 19.2%). The PC-VPC plot (Fig. 2) confirms the adequacy of model predictions, showing no apparent deviations between model and data. The 90% confidence interval and median for observed data lies within the predicted intervals obtained by simulation.
Parameter estimates from the pooled study were suitable for prediction of time -concentration profiles from the index study despite parameter estimate differences between the two studies (Fig. 3) . Simulated subjects of similar age and weight (n¼1000) to those in the pooled study were given propofol 2 mg kg 21 when the Marsh model was used with a weight-corrected formula 16 (Fig. 4) . In addition, this simulation shows that after 3 h of infusion, the predicted context-sensitive halftimes were shorter with the Schnider model (0.7 min) compared with the current pooled model (3.6 min) and longer with the Marsh model (8.8 min). The predicted 80% contextsensitive decrement-times were also shorter with the Schnider model (8.2 min) but very close with the pooled model (51 min) and the Marsh model (55 min) (Fig. 5) . To further validate the anestfusor device used to administer propofol to study patients and to perform the simulation analysis, we compared its performance with Rugloop&, a Windows-based TCI infusion and general data management programme. For this, we used the time and the cumulative infusion (in ml) that anestfusor administered in the TCI simulated scenarios and calculated the differences in the predicted concentrations between both devices. The difference was negligible with a mean of 0.0006 SD 0.007 mg ml 21 . 
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Discussion
This study has shown that an allometric model using TBW as the size descriptor for volumes and clearances in obese patients is superior to other size descriptors. Age also appeared to be an important covariate for the distributional components of propofol PK, which is consistent with the effect on distribution rates described by Schnider and colleagues 17 who showed selective effects on Q2 and V2. The pooled analysis showed that the peripheral volume and its distribution clearance were smaller in older subjects. In our modelling strategy, we first used different size descriptors to explain individual variability. Once size was standardized, the effects of other covariates were tested. In general, our results showed that using TBW was superior to LBM, 27 fat free mass, 28 and no worse than NFM. 29 Although the index study analysis, judged by NONMEM objective function, suggested that the best model was the one where all parameters were scaled linearly per kilogram to TBW (with the exception of elimination clearance which was better using NFM), the larger pooled analysis revealed that allometric scaling using TBW was superior for all parameters. The index study involved only obese patients and therefore body composition was relatively similar, allowing the use of a simple linear scale to normalize the parameters to TBW. Propofol is largely metabolized by the liver, although the kidneys may contribute 27% of total body clearance. 39 40 It has been postulated that long-term changes induced by obesity might cause fatty degeneration of the liver, 14 glomerular injury of the kidneys, or both with a consequent reduction in drug elimination. 4 However, these clearances, unscaled for body size, are usually increased in the obese patient. 41 In obese subjects, clearance does not increase linearly with TBW. 13 Consequently, scaling clearance to LBM instead of TBW has been suggested as a more logical approach. 4 12 13 15 However, the justification for a linear rather than allometric relationship using FFM has not been supported. 42 The use of dosing linear to LBW, where LBW had a non-linear relationship with TBW, has been proposed, but the relationship between LBW and CL for propofol was not estimated from real data. 15 LBW was simply substituted for TBW in the TBW relationship derived from data collected and analysed by others. 43 We have demonstrated that using an allometric relationship between TBW and clearance provides a better description in obese patients. Allometric scaling of clearances using TBW is consistent with other studies 9 -11 and simplifies dosage regimes over a wide range of body weights. A recent study of anticancer drugs found that the values of CL when normalized to BSA, calculated using TBW, were not significantly different between obese and lean patients. 44 These results further support the allometric model used in our study because BSA in humans is approximated with a TBW exponent of 2/3. The allometric 3/4 power model is a non-linear model that has been described as a means of predicting physiological function from body size. Interestingly, a more mechanistic size descriptor, NFM, showed that TBW (Ffat¼1) rather than using another fraction of fat mass gave the best description. It seems that each kilogram of fat mass is equivalent to FFM for describing the size-dependent differences in clearance in obese subjects. The current allometric 3/4 power (non-linear) model for clearance and linear model (exponent of 1) for volume is supported by fractal geometric concepts and observations from diverse areas in biology. 22 Quarter-power scaling laws are widespread in biology with, for example, most organisms having scaling exponents very close to 3/4 for metabolic rate. 26 The pooled data set has patients from 25 to 81 yr, so, in theory, this pooled model should be applicable within this age range, but the data in the elderly are limited. A larger data set over a bigger age range may give a better model. The current model agrees with Schnider PK parameters, 45 the pooled model predicts that younger patients will have faster Q2 and bigger V2 compared with elderly patients. This means that slower initial infusion rates will be predicted by this model in the elderly. Similarities between Schnider 45 and the pooled model with respect to age adjustments are not surprising since most data from elderly patients come from their study. 45 We did not find any influence of gender on propofol PK. These results are in contrast to an earlier study 46 in which younger female patients were found to have higher elimination clearances (per kilogram). These findings could be explained by not accounting for the non-linear relationship of TBW with clearance. However, comparisons between these two studies are difficult as, in that study, 46 formal covariate analysis was not performed, and only the effect of age and gender on V1 and CL1 was explored. One limitation of the index study is the relatively short infusion period (Table 1) and post-infusion sampling times (2 h) that were constrained by clinical limitations. This index study was performed in routinely scheduled patients and as such, ethical and clinical limitations were present. These relatively short observation periods affected the precision of some estimates in our model (V3, V2, and Q2) ( Table 2 ). In general, the longer the infusion duration, the more time there is to distribute to V3 and the better the estimate of V3. When the data of the three studies were pooled, the precision of all estimates was improved and this pooled model adequately characterized the time-concentration profiles (Fig. 3) . A further limitation of our conclusions regarding covariate models is the rather small number of patients (n¼51). It has been pointed out that covariate model conclusion will often be subject to selection bias when the number of subjects is ,100. 47 Nevertheless, we cannot find any support for using anything other than TBW as a size predictor for between-patient differences in propofol PK. Current propofol PK models, used in TCI devices, were derived from studies that did not include morbidly obese patients. 17 36 The current recommendation is that TCI should be used with caution in the obese. 48 The results of our TCI simulated scenario show that the infusion rates predicted by the current pooled model are very similar to those predicted by the Marsh TCI model using TBW as the input function (Fig. 4) . A study of 20 obese patients (ASA physical status II-III, age 32-64 yr) undergoing bariatric surgery, 9 delivering anaesthesia with the Marsh TCI model and the Servin and colleagues 16 corrected weight dosing formula,
showed, in agreement with our predictions, that observed propofol concentrations were consistently lower than the target concentration (under dosing) with a median (range) bias of 232.6% (253.4% to 22.5%).
Our model based on three pooled studies eliminates the need for the James equation 49 used in the Schnider model to calculate LBM. This equation is inappropriate for morbidly obese patients 4 12 28 and results in an overestimation of metabolic clearance in this population. An overestimation of clearance explains the higher infusion rates required to maintain a set concentration and the faster recovery times predicted by this model when compared with Marsh (TBW) and the currently derived pooled model. Shorter recovery times predicted by the Schnider model 17 have also been described in a previous study assessing the predictive performance of different PK models in non-obese healthy subjects. 50 In that study, the Schnider model tended to under-predict propofol concentrations during recovery, with median bias of 215%. This small underestimation during recovery is likely to be magnified in very obese patients from the overestimation of metabolic clearance caused by the James equation. 49 In contrast, Glen and Servin 50 demonstrated that the Marsh model showed an overprediction tendency during the recovery phase with median bias of +10.5%. 50 This is also in agreement with our simulation scenario in an obese patient. We have derived a population PK model using data from obese and non-obese patients to characterize propofol PK over a wide range of body weights. An allometric model using TBW as the size descriptor of volumes and clearances was superior to other size descriptors to characterize propofol PK in the obese. Inclusion of this model into TCI pumps circumvents the need for LBM equations that contribute to inaccurate dosing of the obese.
Supplementary material
Supplementary material is available at British Journal of Anaesthesia online.
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